Caplin Point Laboratories Limited · NSE:CAPLIPOINT
Caplin Point Laboratories — H1 FY25 Earnings Presentation
20 slides from Caplin Point Laboratories's earnings presentation, November 2024
Slide 1: Earnings Presentation H1 FY25
EARNINGS PRESENTATION H1 FY25 Rated #1 in India for “Most Consistent Profitable Growth across the last 10 years” Second Largest wealth creator for the decade ending 2020* November 2024 www.caplinpoint.net #Value Research magazine – Wealth Insight June 2022 issue *The Economic Times
Slide 2: Disclaimer
Disclaimer The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any i
Slide 3: Q2 FY25 Income Statement
Q2 FY25 Income Statement Revenue from Operations Gross Profit EBITDA 18% 20% 18% YoY YoY 483 YoY 294 186 459 273 170 410 246 158 Q2 FY24 Q1 FY25 Q2 FY25 Q2 FY24 Q1 FY25 Q2 FY25 Q2 FY24 Q1 FY25 Q2 FY25 EBIT PAT Earnings Per Share 16% 13% YoY YoY 169 131 16.32 17.22 15.13 125 154 116 146 Q2 FY24 Q1 FY
Slide 4: Q2 FY25 Profit Margins
Q2 FY25 Profit Margins Gross Profit Margins (%) EBITDA Margins (%) 60.9% 36.7% 36.8% 60.0% 59.6% 35.7% Q2 FY24 Q1 FY25 Q2 FY25 Q2 FY24 Q1 FY25 Q2 FY25 EBIT Margins (%) PAT Margins (%) 33.9% 33.5% 27.0% 26.2% 32.3% 26.0% Q2 FY24 Q1 FY25 Q2 FY25 Q2 FY24 Q1 FY25 Q2 FY25 4
Slide 5: H1 FY25 Income Statement
H1 FY25 Income Statement Revenue from Operations Gross Profit EBITDA 17% 23% 20% YoY YoY YoY 942 568 356 463 296 805 H1 FY24 H1 FY25 H1 FY24 H1 FY25 H1 FY24 H1 FY25 EBIT PAT Profit Margins 18% 16% YoY YoY 256 57.4% 60.3% 323 273 220 35.4% 36.3% 32.6% 32.9% 26.3% 26.1% H1 FY24 H1 FY25 H1 FY24 H1 FY25
Slide 6: H1 FY25 Cash and Cash Equivalents and other Key Metrics
H1 FY25 Cash and Cash Equivalents and other Key Metrics Cash and Cash Equivalents Capital Investment Lifecycle 1,039 Cash Flow from 916 Operation: ₹ 186 Cr 772 694 194 146 470 91 284 77 73 77 223 65 47 49 101 126 26 26 27 46 68 8 Free Cashflow: ₹ 109 FY 14 FY 15 FY 16 FY 17 FY 18 FY 19 FY 20 FY 21 F
Slide 7: Leadership Team
Leadership Team Chairman Perspectives Management Team Commenting on the recent performance, Mr. C.C. Paarthipan, Chairman of Caplin Dr. Sridhar Ganesan Mr. Vivek Partheeban Point Laboratories said: • Managing Director • Chief Operating Officer Consistency and Stability are key factors in the sustain
Slide 8: Q2 FY25 Highlights (Emerging Markets)
Q2 FY25 Highlights (Emerging Markets) 01 02 03 04 Amaris Clinical, Caplin Point's Growth aided by new product Caplin One Labs – the CRO division, has completed Company’s Latin America launches in existing and new company’s Oncology business BE/BA studies for 15 in-house business drives robust growth
Slide 9: Q2 FY25 Highlights (US and Regulated markets)
Q2 FY25 Highlights (US and Regulated markets) 01 02 03 04 Caplin Steriles Limited (CSL) Company holds 25 ANDA approvals Company is actively engaging achieves strong revenue growth, (30 including partners) and has 14 with various CMOs to in-license Line-6 qualifications for Pre-Filled driven by Phase
Slide 10: Evolution Over the Decades
Evolution Over the Decades Commences Capex expansion in multiple Incorporates Caplin projects equaling INR 600 Work on Regulated Steriles USA Inc for Listed on Stock Started outsourcing from Started first commercial Cr. CRO wing Amaris Markets Injectable unit launching own label in US Exchange China
Slide 11: Research & Development Capabilities
Research & Development Capabilities 1 Caplin has 5 dedicated R&D setups (3 – DSIR approved and 2 under approval) R&D Expense (Rs. Crore) R&D Expense as a % of Operating Revenue 85 2 Continuous capex investment of over INR 721 Cr over last 8 years towards enhanced manufacturing and R&D capabilities,
Slide 12: Revenue Break up and Manufacturing Strategy
Revenue Break up and Manufacturing Strategy Revenue by Business Segment Revenue by Channel FY24 Operating Revenue (Emerging Markets) (Emerging Markets) 25% 18% 2% 75% 25% 55% 20% 80% Africa US LATAM Generic Branded Generic Wholesale Retail Institutional Caplin covers a wide spectrum of pharmaceutica
Slide 13: Generics and Branded Generics Product Mix
Generics and Branded Generics Product Mix Non-Steroidal Antiinflammatory Antihelminthics/ Dewormer Analgesic Drugs-NSAIDS Antibiotic and Antifungal Antihypertensive drug Electrolytes 13
Slide 14: Caplin Point Structure
Caplin Point Structure Caplin Point Laboratories Caplin Point Far East Ltd Caplin Steriles Ltd (BSE: 524742| NSE: CAPLIPOINT) (India) Subsidiaries Manufacturing Units: • CP I: Puducherry • Caplin Point Laboratories Colombia • CP II: Gummidipoondi SAS Caplin Steriles USA Inc • CP X: Vishakhapatnam •
Slide 15: Manufacturing and R&D Platform
Manufacturing and R&D Platform Tamil Nadu, India Location of Plants and Facilities 11 9 2 4 1. Puducherry (CP I) 8 75 2. Gummidipoondi (CP II) 3 3. Chengalpattu (CP III) 1 4. Gummudipoondi (CP IV) 5. Chennai (CP V) CP I CP III 6. Hyderabad (CP VI) Puducherry Chengalpattu 7. Chennai (CP VII) 8. Chenn
Slide 16: Strategic Investments
Strategic Investments Project Summary Facility Location Product Target Market Status Timeline Lyophilized CP1, Injectables and Caplin Plant I Suthukeny, Existing Markets Ongoing Q4 FY25 Dual Chamber Puducherry Syringes Line 5-Completed CP4, Injectable Vials Caplin Steriles Line 6-Qualification Gummi
Slide 17: Caplin Point's Investment Case
Caplin Point’s Investment Case Core Business to show consistent Caplin’s core business which is focused on Latin America and Francophone Africa is expected to grow at a growth steady pace with industry-average margins and benchmark cashflows Aspiration is to have exceptional compliance record and fo
Slide 18: Experienced and Visionary Board of Directors
Experienced and Visionary Board of Directors Mr. C.C. Paarthipan Dr. Sridhar Ganesan D Sathya Narayanan Dr. C K Gariyali, IAS Dr. R Nagendran Mr S Deenadayalan Mr. R. Vijayaraghavan Chairman Managing Director Independent Director Independent Director Independent Director Independent Director Indepen
Slide 19: P&L for the Q2 FY25 – Consolidated
P&L for the Q2 FY25 – Consolidated Value (₹ in Cr) Q2 FY25 Q2 FY24 YoY (%) Q1 FY25 QoQ (%) H1 FY25 H1 FY24 YoY (%) Revenue from Operation 483.10 410.06 17.8% 458.96 5.3% 942.06 805.38 17.0% Other Income 20.77 20.43 18.56 39.33 32.47 Total Revenue 503.87 430.49 17.0% 477.52 5.5% 981.39 837.85 17.1% C
Slide 20: Investor Relations at Caplin
INVESTOR RELATIONS AT CAPLIN Mr G Venkatram [email protected] CHURCHGATE PARTNERS Rajiv Pandya / Anvita Raghuram [email protected] 524742 CAPLIPOINT CIN: L24231TN1990PLC019053 ISIN: INE475E01026 |DUNS:86-148-4556 | WWW.CAPLINPOINT.NET ©2018, Caplin Point Laboratories Limited
Caplin Point Laboratories — H1 FY25 Earnings Presentation on 6ix